Research
Hormonal
An active perioperative GLP-1 RA prescription in patients with diabetes was associated with a significantly reduced risk of 30-day readmission (RR: 0.883; P = 0.028).
Practitioners may consider GLP-1 RA prescriptions to reduce readmission rates in diabetic surgical patients.
StrongSupportsmedium confidence
After matching, the active GLP-1 RA prescription group had a significantly reduced risk of 30-day readmission [relative risk (RR): 0.883; 95% CI: 0.789-0.987; P = 0.028].
Why this rating
Based on a large retrospective cohort analysis.
Source
Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes
Seth Z. Aschen et al. · Annals of Surgery · 2024
DOI 10.1097/sla.0000000000006614
cohort · n=21772Cited 39×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →